Ting Joseph Y S, Barns Kenneth J, Holmes John L
Department of Emergency Medicine, Mater Adults' Hospital, Raymond TCE, South Brisbane, 4101 Qld, Australia.
J Emerg Trauma Shock. 2009 Jan;2(1):10-4. doi: 10.4103/0974-2700.44676.
It is unclear whether local anesthetic eye drops can be safely used for the topical anesthesia of patients with minor corneal injury who are discharged from the emergency department (ED).
To assess whether topical 0.4% amethocaine self-administered to a maximum recommended frequency of once every hour for 36-48 h is safe in the management of uncomplicated corneal injury in patients discharged from the ED.
A pilot randomized double-blinded trial comparing topical 0.4% amethocaine with topical normal saline.
Forty-seven subjects were recruited, with 22 randomized to receive amethocaine and 25 to receive placebo (normal saline). Baseline characteristics, including corneal injury type, were similar in both groups. There were no significant functional or clinical adverse sequelae in the majority of enrolled patients who could be contacted at 2 weeks (17/22 for amethocaine and 21/25 for placebo). Follow-up for the primary study outcome was suboptimal, with only 7/22 from the amethocaine group and 9/25 from the saline group presenting for 36-48 h review; there was a statistically nonsignificant trend for persistence of the corneal defect in the amethocaine group as compared with the saline group (2/7 and 1/9, respectively).
Compared with saline drops, amethocaine eye drops are not definitely safe but they are effective for topical analgesia in minor corneal injury. Until further definitive studies, topical nonsteroidal agents or long-lasting artificial tears may be preferred for the topical analgesia of minor corneal injury. Return for corneal re-evaluation will necessarily remain suboptimal in an otherwise self-limiting condition, leading to a bias even if study recruitment is good.
对于从急诊科出院的轻度角膜损伤患者,局部麻醉眼药水是否可安全用于局部麻醉尚不清楚。
评估对于从急诊科出院的单纯性角膜损伤患者,局部使用0.4%丁卡因,以每小时一次的最大推荐频率给药36 - 48小时是否安全。
一项试点随机双盲试验,比较局部使用0.4%丁卡因与局部使用生理盐水。
招募了47名受试者,其中22名随机接受丁卡因,25名接受安慰剂(生理盐水)。两组的基线特征,包括角膜损伤类型,相似。在2周时能够联系到的大多数入组患者中,没有显著的功能或临床不良后遗症(丁卡因组17/22,安慰剂组21/25)。主要研究结局的随访不理想,丁卡因组仅7/22、生理盐水组仅9/25前来进行36 - 48小时复查;与生理盐水组相比,丁卡因组角膜缺损持续存在的趋势无统计学意义(分别为2/7和1/9)。
与生理盐水滴眼液相比,丁卡因滴眼液不一定安全,但对轻度角膜损伤的局部镇痛有效。在有进一步确定性研究之前,局部使用非甾体类药物或长效人工泪液可能更适合用于轻度角膜损伤的局部镇痛。在这种自限性疾病中,角膜重新评估的回访必然不理想,即使研究招募情况良好也会导致偏差。